Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | CTRB1 | P17538 | 4/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | SCN4A | P35499 | 2/20 | 0.46 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11947654 | 0.87 | EPHX2 (0.48) | MMP2NPC1RAB9ACTSLCTSB | |
| SCHEMBL11947664 | 0.86 | SLC6A4 (0.49) | — | |
| SCHEMBL17045283 | 0.85 | MMP2 (0.51) | MMP2EPHX1SCN4A | |
| SCHEMBL17045285 | 0.85 | MMP2 (0.51) | MMP2EPHX1SCN4A | |
| SCHEMBL11947651 | 0.85 | MMP2 (0.51) | MMP2EPHX1SCN4A | |
| SCHEMBL17045249 | 0.84 | MMP2 (0.50) | MMP2EPHX1SCN4A | |
| SCHEMBL17045247 | 0.84 | MMP2 (0.50) | MMP2EPHX1SCN4A | |
| SCHEMBL11947649 | 0.84 | MMP2 (0.50) | MMP2EPHX1SCN4A | |
| SCHEMBL17045233 | 0.82 | MMP2 (0.51) | MMP2EPHX1ATM | |
| SCHEMBL17045235 | 0.82 | MMP2 (0.51) | MMP2EPHX1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232315-B2 | Methods for treating drug addiction and improving addiction-related behavior | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2012-07-31 | — | — | US | disclosed |
| US-20100331332-A1 | METHODS FOR TREATING DRUG ADDICTION AND IMPROVING ADDICTION-RELATED BEHAVIOR | SK HOLDINGS CO., LTD. (KR) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331332-A1 | METHODS FOR TREATING DRUG ADDICTION AND IMPROVING ADDICTION-RELATED BEHAVIOR | CES2, SLC6A3, CHAT | MMP2 2051/4885NPC1 722/4885RAB9A 1217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.